We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+14.5%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$340M
AUM Growth
+$94.6M
Cap. Flow
+$76.8M
Cap. Flow %
22.61%
Top 10 Hldgs %
47.34%
Holding
100
New
32
Increased
8
Reduced
12
Closed
21

Top Buys

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$16.1M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$12.2M
3
CRBP icon
Corbus Pharmaceuticals
CRBP
+$9.98M
4
GKOS icon
Glaukos
GKOS
+$9.58M
5
ARWR icon
Arrowhead Research
ARWR
+$8.66M

Top Sells

Rank Stock Value
1
ALIM
Alimera Sciences
ALIM
+$12M
2
ARGX icon
argenx
ARGX
+$9.89M
3
ASND icon
Ascendis Pharma A/S
ASND
+$6.82M
4
INSM icon
Insmed
INSM
+$4.43M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.51M

Sector Composition

Rank Sector Weight
1 Healthcare 97.3%
2 Consumer Discretionary 1.17%
3 Consumer Staples 0.08%
4 Industrials 0.03%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMN icon
51
ProMIS Neurosciences
PMN
$132M
$727K 0.21%
+23,256
New +$868K
MIST icon
52
Milestone Pharmaceuticals
MIST
$152M
$669K 0.2%
440,000
-572,368
-57% -$833K
KPTI icon
53
Karyopharm Therapeutics
KPTI
$48M
$614K 0.18%
49,333
– –
UNCY icon
54
Unicycive Therapeutics
UNCY
$139M
$601K 0.18%
+147,300
New +$592K
FATBW
55
DELISTED
FAT Brands Inc. Warrant
FATBW
$499K 0.15%
200,000
– –
APLT
56
PUT
DELISTED
Applied Therapeutics
APLT
$477K 0.14%
+56,100
New +$331K
CLRB icon
57
Cellectar Biosciences
CLRB
$20.5M
$460K 0.14%
+7,167
New +$473K
XENE icon
58
CALL
Xenon Pharmaceuticals
XENE
$6.12B
$370K 0.11%
+9,400
New +$379K
SRXH
59
SRX Global
SRXH
$31M
$278K 0.08%
+2,995
New +$400K
XPON icon
60
Expion360
XPON
$3.31M
$106K 0.03%
+1,715
New +$716K
NXGLW icon
61
NexGel Inc Warrant
NXGLW
$91.5K 0.03%
225,000
– –
SCPX
62
DELISTED
Scorpius Holdings, Inc.
SCPX
$63.6K 0.02%
+4,415
New +$107K
RCKTW icon
63
Rocket Pharmaceuticals Warrant
RCKTW
$288K
$51.2K 0.02%
731,561
– –
ONFOW icon
64
Onfolio Holdings Warrant
ONFOW
$64.5K
$34K 0.01%
200,000
– –
WLDSW icon
65
Wearable Devices Ltd Warrant
WLDSW
$132K
$28.1K 0.01%
1,961
– –
MOBXW icon
66
Mobix Labs Warrants
MOBXW
$752K
$22.3K 0.01%
150,000
– –
CINGW icon
67
Cingulate Inc Warrants
CINGW
$33.2K
$18.7K 0.01%
270,000
– –
NKTR icon
68
Nektar Therapeutics
NKTR
$2.58B
$14.8K ﹤0.01%
+761
New +$14.5K
NXLIW
69
DELISTED
Nexalin Technology Inc Warrant
NXLIW
$8.4K ﹤0.01%
105,000
– –
BNCWW
70
CEA Industries Inc Warrant
BNCWW
$6.28K ﹤0.01%
250,000
– –
VSEEW
71
VSEE HEALTH INC WTS 29
VSEEW
$6K ﹤0.01%
150,000
– –
BTMWW
72
DELISTED
Bitcoin Depot Inc Warrant
BTMWW
$2.5K ﹤0.01%
50,000
– –
NEXRW
73
Nexera Technologies Ltd Warrant
NEXRW
$48.9K
$2.44K ﹤0.01%
68,681
– –
NLSPW
74
DELISTED
NLS Pharmaceutics Warrant
NLSPW
$2.28K ﹤0.01%
200,000
– –
CYCUW
75
Cycurion Inc Warrant
CYCUW
$311K
$2.18K ﹤0.01%
100,000
– –
1 2
3
4

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Altium Capital Management held 100 positions worth $340M, up 39% from $245M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Altium Capital Management deployed $76.8M of net new capital in Q3 2024, opening 32 new positions and adding to 8 existing holdings. Its largest new stake was Edwards Lifesciences: 222,000 shares worth $14.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was Insmed, an estimated $4.43M trimmed.

  • Altium Capital Management's largest Q3 2024 buy was Edwards Lifesciences: 222,000 shares worth $14.6M.
  • Altium Capital Management added most to Sarepta Therapeutics in Q3 2024, an estimated $12.2M increase.
  • Altium Capital Management's biggest Q3 2024 reduction was Insmed, cutting an estimated $4.43M.
  • Altium Capital Management fully exited Alimera Sciences in Q3 2024, selling an estimated $12M.
  • Altium Capital Management's ten largest holdings make up 47% of its $340M portfolio in Q3 2024.
  • Altium Capital Management opened 32 new positions and closed 21 in Q3 2024.
  • Altium Capital Management's portfolio value rose 39% quarter-over-quarter to $340M.

Based on Altium Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.